A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework.
The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response
Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view.
AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
